Literature DB >> 17457183

Safety of UVA-riboflavin cross-linking of the cornea.

Eberhard Spoerl1, Michael Mrochen, David Sliney, Stephen Trokel, Theo Seiler.   

Abstract

PURPOSE: To study potential damage to ocular tissue during corneal collagen cross-linking (X-linking) by means of the riboflavin/UVA (370 nm) approach.
METHODS: Comparison of the currently used technique with officially accepted guidelines regarding direct UV damage and the damage created by the induced free radicals (photochemical damage).
RESULTS: The currently used UVA radiant exposure of 5.4 mJ/cm and the corresponding irradiance of 3 mW/cm2 is below the known damage thresholds of UVA for the corneal endothelium, lens, and retina. Regarding the photochemical damage caused by the free radicals, the damage thresholds for keratocytes and endothelial cells are 0.45 and 0.35 mW/cm, respectively. In a 400-microm-thick cornea saturated with riboflavin, the irradiance at the endothelial level was 0.18 mW/cm, which is a factor of 2 smaller than the damage threshold.
CONCLUSIONS: After corneal X-linking, the stroma is depopulated of keratocytes approximately 300 microm deep. Repopulation of this area takes up to 6 months. As long as the cornea treated has a minimum thickness of 400 microm (as recommended), the corneal endothelium will not experience damage, nor will deeper structures such as lens and retina. The light source should provide a homogenous irradiance, avoiding hot spots.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457183     DOI: 10.1097/ICO.0b013e3180334f78

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  176 in total

1.  Using the Griess colorimetric nitrite assay for measuring aliphatic β-nitroalcohols.

Authors:  Quan Wen; David C Paik
Journal:  Exp Eye Res       Date:  2012-03-03       Impact factor: 3.467

2.  Corneal collagen crosslinking for corneal ectasia of post-LASIK: one-year results.

Authors:  Gang Li; Zheng-Jun Fan; Xiu-Jun Peng
Journal:  Int J Ophthalmol       Date:  2012-04-18       Impact factor: 1.779

3.  Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: chemical stability studies using 1H-NMR spectroscopy.

Authors:  Xia Li; Yongjun Li; Mijung Kim; Stephen L Trokel; Nicholas J Turro; David C Paik
Journal:  Photochem Photobiol       Date:  2013-10-21       Impact factor: 3.421

4.  Biomechanical property analysis after corneal collagen cross-linking in relation to ultraviolet A irradiation time.

Authors:  Elena Lanchares; María Angeles del Buey; José Angel Cristóbal; Laura Lavilla; Begoña Calvo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

Review 5.  Corneal collagen crosslinking in keratoconus and other eye disease.

Authors:  Adel Alhayek; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

6.  Pulsed vs continuous light accelerated corneal collagen crosslinking: in vivo qualitative investigation by confocal microscopy and corneal OCT.

Authors:  C Mazzotta; C Traversi; S Caragiuli; M Rechichi
Journal:  Eye (Lond)       Date:  2014-07-25       Impact factor: 3.775

7.  Patterned corneal collagen crosslinking for astigmatism: computational modeling study.

Authors:  Ibrahim Seven; Abhijit Sinha Roy; William J Dupps
Journal:  J Cataract Refract Surg       Date:  2014-04-24       Impact factor: 3.351

Review 8.  Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

Authors:  Maria Gkika; Georgios Labiris; Vassilios Kozobolis
Journal:  Int Ophthalmol       Date:  2011-08-17       Impact factor: 2.031

9.  Human eye ocular component analysis for refractive state and refractive surgery.

Authors:  Chao-Kai Chang; Jui-Teng Lin; Yong Zhang
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

Review 10.  Corneal collagen cross-linking for keratoconus and post-LASIK ectasia.

Authors:  Ronald N Gaster; Ana L Caiado Canedo; Yaron S Rabinowitz
Journal:  Int Ophthalmol Clin       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.